Loading clinical trials...
Loading clinical trials...
Phase II Study of Adjuvant Nivolumab in Patients With Resected Stage IIB/IIC Melanoma
Conditions
Interventions
Nivolumab
Locations
4
United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Columbia University
New York, New York, United States
Univeristy of Pennsylvania
Philadelphia, Pennsylvania, United States
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Start Date
January 17, 2018
Primary Completion Date
December 15, 2025
Completion Date
December 15, 2025
Last Updated
December 31, 2025
NCT06956690
NCT05649683
NCT00003641
NCT03543969
NCT04079166
NCT05492682
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions